An interventional study of the investigators give inositol for two months. in Polycystic Ovarian Syndrome (PCOS), sponsored by Karadeniz Technical University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Karadeniz Technical University · Not applicable, Interventional, and Other
This prospective observational cohort study aims to evaluate longitudinal changes in metabolic status and cardiopulmonary exercise capacity in women with polycystic ovary syndrome (PCOS). Women aged 18-45 years with classic phenotype A PCOS who have initiated inositol treatment will be included.
At baseline, participants will undergo cardiopulmonary exercise testing using the COSMED K5 metabolic system, with assessment of VO₂max/VO₂peak and exercise-related metabolic parameters. Body composition, including body fat percentage, fat-free mass, fat mass, and phase angle, will also be assessed using bioelectrical impedance analysis. The same measurements will be repeated after two months to evaluate longitudinal changes.
The primary objective is to quantitatively assess the metabolic response of patients with PCOS during clinical follow-up using cardiopulmonary exercise testing. The secondary objective is to characterize temporal changes in metabolic parameters during the treatment period.
One-sentence version:
This study aims to evaluate longitudinal changes in cardiopulmonary exercise capacity and metabolic parameters in women with classic phenotype PCOS receiving inositol treatment over a two-month follow-up period using COSMED K5 cardiopulmonary exercise testing and bioelectrical impedance analysis.
975 studies on the registry are indexed under Polycystic Ovary Syndrome; 177 are open to participants now.
This study's enrollment of 45 is below the median of 70 across 710 interventional studies indexed under Polycystic Ovary Syndrome.
Browse Polycystic Ovary Syndrome studies →Karadeniz Technical University is the lead sponsor of 150 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
following this arm
Dietary Supplement: the investigators give inositol for two months.
the investigators give inositol for two months. and then the investigators assesment metabolism on all patients.
Outcome Measure vo2max
Outcome Measure: Change in VO₂max/VO₂peak Time Frame: Baseline to 2 months Description: VO₂max/VO₂peak will be measured during cardiopulmonary exercise testing using the COSMED K5 metabolic system at baseline and after 2 months.
Time frame: 2 months
Outcome Measure: Change in VO₂max/VO₂peak
Time Frame: Baseline to 2 months Description: VO₂max/VO₂peak will be measured during cardiopulmonary exercise testing using the COSMED K5 metabolic system at baseline and after 2 months.
Time frame: two months
Plan to share: No — No. Individual participant-level data will not be made available to other researchers.
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Sep 2026, 7 months.
Of 206 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 7 months is below that.
Counting every sponsor, half of 221 studies reached it within 18 months; a quarter within 7 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Karadeniz Technical University →